SAGE INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into Sage Therapeutics, Inc. and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Sage Therapeutics, Inc. (NASDAQ: SAGE) focused on whether Sage Therapeutics and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.

If you have information that could assist in this investigation or if you are a Sage Therapeutics investor who suffered a loss and would like to learn more, you can provide your information here:

https://www.rgrdlaw.com/cases-sage-therapeutics-inc-investigation-sage.html

You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at jsanchez@rgrdlaw.com.

THE COMPANY: Sage Therapeutics is a biopharmaceutical company that develops and commercializes brain health medicines. On December 6, 2022, Sage Therapeutics and Biogen Inc. announced the completion of the rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for zuranolone in the treatment of major depressive disorder (“MDD”) and postpartum depression (“PPD”). Zuranolone is an investigational drug being evaluated as a rapid-acting, once-daily, 14-day oral short course treatment in adults with MDD and PPD.

THE REVELATION: On August 4, 2023, Sage Therapeutics disclosed that “the FDA issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for zuranolone in the treatment of adults with major depressive disorder (MDD). The CRL stated that the application did not provide substantial evidence of effectiveness to support the approval of zuranolone for the treatment of MDD and that an additional study or studies will be needed.” Following this news, the price of Sage Therapeutics stock declined by more than 43%.

ABOUT ROBBINS GELLER RUDMAN & DOWD LLP: Robbins Geller is one of the world’s leading complex class action firms representing plaintiffs in securities fraud cases. The Firm is ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report for recovering more than $1.75 billion for investors in 2022 – the third year in a row Robbins Geller tops the list. And in those three years alone, Robbins Geller recovered nearly $5.3 billion for investors, more than double the amount recovered by any other plaintiffs’ firm. With 200 lawyers in 9 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest securities class action recovery ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Attorney advertising.

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230814053664/en/